Transarterial Chemoembolization (TACE) Market Research Report - Forecast till 2030

Transarterial Chemoembolization (TACE) Market Research Report: By Procedure Type (Conventional TACE, DEB-TACE), Indication (Unresectable HCC, Early-Stage HCC), Product Type (Chemotherapeutic Agents, Radiotherapeutic Agents, Drug-eluting Particles), End-User (Hospitals & Clinics, Cancer Research Centers) - Forecast to 2030

ID: MRFR/HC/7092-HCR | February 2023 | Region: Global | 125 Pages         

Transarterial Chemoembolization Market Speak to Analyst Request a Free Sample

Transarterial Chemoembolization (TACE) Market

Transarterial Chemoembolization (TACE) Market to register a CAGR of 4.90% and reach a value of USD 15.61 Billion by 2030.

By Procedure Type Conventional TACE DEB-TACE
By Indication Unresectable HCC Early-Stage HCC
By Product Type Chemotherapeutic Agents Radiotherapeutic Agents Drug-eluting Particles
By End-User Hospitals & Clinics Cancer Research Centers
Key Players
Companies Profiled   Advaxis Inc. (US)   Baxter (US)   Bellicum Pharmaceuticals   Boston Scientific Corporation (US)   Cook (US)   Hikma Pharmaceuticals PLC (UK)   Isofol Medical AB (Sweden)   Nippon Kayaku Co.   Novartis (Switzerland)   Pfizer (US)   Sirtex SIR-Spheres Pty Ltd. (Australia)   Spectrum Pharmaceuticals
Market Driving Forces   rising incidence of liver cancer   increase in medication usage and development
Request a Free Sample

Market overview

According to the latest research report,the transarterial chemoembolization (TACE) market is projected to reach USD 15.61 Billion by 2030 at 4.90% CAGR during the forecast period 2022-2030. Hepatocellular carcinoma is a primary tumour of the liver that develops mostly as a result of chronic liver problems and cirrhosis in the majority of cases. The disease affects over 500,000 individuals globally and is the 3rd largest cause of cancer mortality in the globe. Persons with intermediate-stage hepatocellular carcinoma are now treated with transarterial chemoembolization, which is the gold standard of care (HCC). Therefore, TACE is regarded as standard therapy for HCC in the conventional sense.

The use of transarterial chemoembolization accomplishes treatment for liver cancer. It operates on the principle of cutting off the blood flow to the tumour. Once a supply has been cut off, chemotherapy is administered directly into the tumour. Treatment for people with intermediate-stage hepatocellular carcinoma is administered intravenously. Conventional transarterial chemoembolization market is regarded to be the standard gold therapy for HCC in the United States. It is also possible to utilize microspheres as drug carriers during transarterial chemoembolization, which may minimize the level of chemotherapeutics in the patient's systemic circulation.

This report contains all the information on the global Transarterial Chemoembolization (TACE) Market analysis and its strengths. In addition, the report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the global Transarterial Chemoembolization (TACE) Market forecast for 2025 is also included in the report.

Covid 19 Analysis

Pharma and biotech businesses are helping governments worldwide combat the COVID-19 pandemic, from drug trials to drug supply chain difficulties. Current vaccine candidates and compounds under R&D total roughly 115. Moreover, regularly used medications like Hydroxychloroquine have shown an increase in demand for COVID-19 control. The enormous demand for COVID-19 management medications has created tremendous potential for producers since many industrialized nations are experiencing shortages. The need for COVID-19 vaccines and treatment medications is predicted to fuel future development in the biopharmaceutical industry. This will have a major influence on the transarterial chemoembolization business.

Market Dynamic


It is anticipated that the rising incidence of liver cancer would fuel the expansion of the transarterial chemoembolization (TACE) market growth. HCC is the fifth most commonly diagnosed cancer in the world, and it is the second greatest cause of cancer mortality in males throughout the globe. High-grade cervical cancer is more common in Asia and Africa.


With the increasing frequency of hepatocellular carcinoma (HCC), around 750,000 new cases are diagnosed annually across the globe. In addition, the prevalence of hepatitis B virus (HBV) as well as hepatitis C virus (HCV) infections keeps rising, as seen by the charts on the website. Another factor propelling the expansion of the transarterial chemoembolization (TACE) market value is the continuous increase in medication usage and development.


Although rare, the death of a trained expert during therapy is likely to have a negative impact on market expansion during the projection period.


The transarterial chemoembolization (TACE) market faces many challenges, including complications following blockage and an elevated cost of treatment. 

Cumulative Growth Analysis

Clients with intermediate-stage hepatocellular carcinoma are now treated with transarterial chemoembolization market, which is the gold standard of care. TACE is regarded as standard therapy for HCC in the conventional sense. TACE with drug-eluting beads, on the other hand, has been introduced as a result of toxicities caused by conventional TACE in certain circumstances. DEB-TACE is a drug delivery system that employs microspheres to lower the concentration of chemotherapeutics in sufferers' systemic circulation.

The rising prevalence of high-grade cervical cancer (HCC) is a major driver of the transarterial chemoembolization (TACE) business. HCC accounts for roughly 70% to 90% of all primary liver malignancies and is the 3rd most lethal malignancy in the world, according to the World Cancer Research Fund. Inoperable HCC patients may consider transarterial chemoembolization market as a palliative treatment option among the many available options. HCC, on the other hand, necessitates the use of repeated cycles of TACE therapy.

Value Chain Analysis

According to the reports, the global Transarterial Chemoembolization (TACE) Market is segmented on the basis of procedure type, indications, product type, end-users, and regions. Transarterial chemoembolization is one of the earliest techniques utilized in HCC patients. In TACE, chemotherapy medicines are infused using lipiodol and embolic agents into the cancer-feeding artery. The DEB-TACE category will expand the quickest. Compared to TACE, DEB-TACE provides greater drug concentrations to the target tumour and lower systemic amounts. Therefore, TACE is a key therapy option for HCC. Unresectable HCC is a liver tumour that cannot be resected due to disease extent.

Chemotherapeutic Agents dominated the market in 2018. TACE frequently uses cisplatin, doxorubicin, and mitomycin. Doxorubicin is the most often utilized TACE HCC chemotherapy. Dosage varies from 30 to 75 mg/m2. TACE plus radiotherapy is the priciest liver tumour treatment. TACE uses drug-eluting beads as a new medication delivery system. DC Beads are a popular drug-eluting bead. These beads are PVA microspheres laced with doxorubicin. The greatest Transarterial Chemoembolization (TACE) Market share is held by Hospitals & Clinics because of a growth in HCC patients, institutions, quality treatment, and accessibility of experienced and competent experts. The fastest expanding category is Cancer Research Centers, driven by increased financing for HCC studies.

Segmentation Overview

The market is segmented based on procedure type, indications, product type, end-users, and regions. The global Transarterial Chemoembolization (TACE) Market trends are expected to witness decent growth during the forecast period.

By Application

Based on the Application, the market is segmented into Chemotherapeutic Agents, Radiotherapeutic Agents, and Drug-eluting Particles.

By end-users

Based on the propulsion types, the market is segmented into Hospitals & Clinics and Cancer Research Centers.

Regional Analysis

According to the reports, on the basis of regions, the global Transarterial Chemoembolization (TACE) Market is divided into America, Europe, Asia Pacific, and the middle east and Africa. Transarterial chemoembolization (TACE) market is seeing tremendous growth in America because of increased knowledge of HCC and early detection. Therefore, the American Association of Liver Diseases suggests that individuals at danger for HCC undergo hepatic imaging once 6 months to monitor their condition. The healthcare systems of Europe are among the greatest in the world. Therefore, transarterial chemoembolization (TACE) market is seeing an increase in demand owing to increase healthcare costs. ACCORDING TO THE EUROPEAN COMMISSION, total EU government spending stood for 45.8% of GDP in 2017, while health care spending accounted for a 7.0% share of GDP.

As the world's most populous continent and a location where hepatocellular carcinoma is becoming more and more common, Asia-Pacific is home to the fastest-growing TACE global market. There have been a large number of incidents in Asian nations. China alone accounts for half of all cases globally. 70% to 80% of all cases of hepatocellular carcinoma in Asia are caused by the hepatitis B virus, with Japan being the exception.

There are two primary regions in the Middle East and Africa: the Middle East and Africa. Over the projection period of 2019 to 2025, the Middle East healthcare market is predicted to rise due to positive government efforts, current healthcare changes, and increasing healthcare facilities.

Competitive landscape

Creativity, acquisition, and mergers were among the primary tactics businesses participating in the Transarterial Chemoembolization (TACE) Market outlook.

Transarterial Chemoembolization (TACE) Market Major Key Players

  • Advaxis Inc. (US)

  • Baxter (US)

  • Bellicum Pharmaceuticals, Inc. (US)

  • Boston Scientific Corporation (US)

  • Cook (US)

  • Hikma Pharmaceuticals PLC (UK)

  • Isofol Medical AB (Sweden)

  • Nippon Kayaku Co., Ltd. (Japan)

  • Novartis (Switzerland)

  • Pfizer (US)

  • Sirtex SIR-Spheres Pty Ltd. (Australia)

  • Spectrum Pharmaceuticals, Inc. (US)

  • Jiangsu Hengrui Medicine Co., Ltd. (China)

Report Overview

The following report comprises of ‚Äď

  • Market overview¬†

  • Covid 19 Analysis

  • Market Dynamic

  • Drivers

  • Opportunities

  • Restraints¬†

  • Challenges

  • Cumulative Growth Analysis

  • Value Chain Analysis

  • Segmentation Overview¬†

  • By Application¬†

  • By End-Users

  • Regional Analysis

  • Competitive landscape

Recent Developments

  • Durvalumab is now being studied in three Phase 3 trials by AstraZeneca. As a monoclonal antibody, it inhibits the programmed cell death-1-ligand 1 (PD-L1) binding to PD-1. EMERALD-1 is one of the trials now underway. Durvalumab monotherapy was shown to be safe and effective in a study published in June of last year.


By Procedure Type

  • Conventional TACE


By Indication

  • Unresectable HCC

  • Early-Stage HCC¬†

By Product Type

  • Chemotherapeutic Agents

  • Radiotherapeutic Agents

  • Drug-eluting Particles

By End-User

  • Hospitals & Clinics

  • Cancer Research Centers¬†

By Region

  • Americas

  • Europe.

  • Asia-Pacific

  • Middle East & Africa

Report Scope:

Report Attribute/Metric Details
  Market Size   15.61 Billion
  CAGR   4.90%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Procedure Type, Product Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors    Advaxis Inc. (US), Baxter (US), Bellicum Pharmaceuticals, Inc. (US), Boston Scientific Corporation (US), Cook (US), Hikma Pharmaceuticals PLC (UK), Isofol Medical AB (Sweden), Nippon Kayaku Co. Ltd. (Japan), Novartis (Switzerland), Pfizer (US), Sirtex SIR-Spheres Pty Ltd. (Australia), Spectrum Pharmaceuticals Inc. (US), Jiangsu Hengrui Medicine Co. Ltd. (China)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of hepatocellular carcinoma\r\n
  • Increasing spending on the pharmaceutical industry\r\n
  • Growing drug consumption and drug development rates\r\n
  • Increasing R&D expenditure

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The Transarterial Chemoembolization (TACE) Market CAGR would be 4.90% during the forecast period.

    The Transarterial Chemoembolization (TACE) Market size was USD 1559.2 million in 2018.

    The unresectable HCC segment holds the maximum market share.